$TROX

Tronox Announces Signing of a Cooperation and Investment Agreement with JX Advanced Metals to Advance Rare Earth Strategy

Tronox (TROX) and JXAM (5016) signed a 50/50 agreement to invest $32M in feasibility studies for rare earth processing facilities in Australia and the U.S. The project aims to produce 10,000 tonnes of rare earth oxides annually, supporting high-tech industries. If viable, they may form a joint venture for construction and operation.

Original reporting
Published Sep 29, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tronox Announces Signing of a Cooperation and Investment Agreement with JX Advanced Metals to Advance Rare Earth Strategy — source image
Decision brief

The 30-second read

$TROXBullishMed
01

Why it matters

The joint investment signals a strategic shift toward critical minerals, potentially diversifying revenue and reducing reliance on pigment markets.

02

Market read

First disclosure of a $32 M joint feasibility effort, creating a new growth avenue for both firms and the broader critical‑minerals sector.

03

What to watch

Potential regulatory, environmental approvals and financing uncertainties could delay or cancel projects.

Relevance 7/10Novelty 7/10Timing: announcement today

Background

Tronox, a leading TiO2 pigment producer, is expanding into rare‑earth processing to capture growing demand from high‑tech industries.

Company-level read

Ticker impact

$TROXBullishHigh confidence
Context

Tronox announced a $32 million 50/50 investment with JX Advanced Metals to fund feasibility studies for rare‑earth processing facilities in Australia and the United States.

Expected impact

likely upward pressure as investors price in potential growth from rare‑earth projects.

Evidence & confidence

The agreement is the first public disclosure of a sizable joint‑venture effort, indicating strategic expansion beyond TiO2.

Market effects

strengthens the critical‑minerals and rare‑earth sector, may boost related mining and materials stocks.

supports US, Australian and Japanese strategic mineral supply chains, could attract government financing.

adds to global diversification of rare‑earth supply, relevant for semiconductor and defense supply chains.

Counterpoint

If feasibility studies reveal high costs or technical hurdles, the partnership could become a financial drain.

Key entities

  • Tronox Holdings plc

    US‑listed titanium dioxide producer entering rare‑earth partnership.

  • JX Advanced Metals Corp.

    Japanese advanced materials firm partnering on rare‑earth projects.

Related articles

$TROXMedAI 8/10

Tronox (TROX) Q2 2026 Earnings Call Transcript

Tronox (TROX) reported Q2 2026 revenue of $868 million, up 19%, driven by higher TiO2 and zircon volumes. Net loss was $171 million, including a $103 million tax valuation allowance. Adjusted EBITDA fell 22% to $73 million. Free cash flow was $60 million. Q3 2026 adjusted EBITDA guidance is $95 million to $115 million.

$TROXMed

Tronox Q2 Earnings Call Highlights

Tronox (NYSE:TROX) said it is shifting from temporary TiO2 and zircon surcharges to more sustainable pricing. CFO John Srivisal cited pricing as the largest driver of expected Q3 earnings improvement, alongside outage and cost-program benefits. Tronox expects Q3 adjusted EBITDA of $95M to $115M, net debt of $3.0B, and India duty recommendations on Chinese TiO2.

$TROXMed

Tronox Reports Second Quarter 2026 Financial Results

Tronox Holdings plc (TROX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tronox Reports Second Quarter 2026 Financial Results STAMFORD, Conn., August 5, 2026/PRNewswire/ — Tronox Holdings plc (NYSE:TROX) (“Tronox” or the “Company”), the world’s leading integrated manufacturer of titanium dioxide (“TiO 2 ”) pigment, today reported its fina

$TROXMedAI 8/10

Tronox Reports Second Quarter 2026 Financial Results

Tronox Holdings plc (NYSE:TROX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue rose to $868 million, up 19% year over year. It posted a GAAP net loss of $171 million, or $1.07 per diluted share, and adjusted net loss of $82 million. Adjusted EBITDA was $73 million. The company expects full-year 2026 positive free cash flow and Q3 adjusted EBITDA of $95-$115 million.

$GKOSMedAI 8/10

Glaukos' Epioxa Shows Durable Benefits At Three Years In Keratoconus Study

Glaukos (GKOS) reported positive three-year data from a Phase 3 extension study of Epioxa, its corneal cross-linking therapy for keratoconus. The study showed durable efficacy and a favorable safety profile, with treated eyes showing sustained improvement in corneal curvature and visual acuity. GKOS reported a narrowed net loss and 50% sales growth in Q2 2026, with 2026 net sales guidance of $680M-$700M. The stock is up 6.55% on the day.

$ADXNMedAI 8/10

Addex Therapeutics: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Addex Therapeutics (ADXN) announced its spin-out, Neurosterix, completed Phase 1 trials for NTX-253, a schizophrenia treatment. Neurosterix plans to advance NTX-253 to Phase 2. Addex holds a 20% stake in Neurosterix, which raised $65M in Series A funding. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, showing promising preclinical results.